Understanding the Current Rating
The 'Hold' rating assigned to Themis Medicare Ltd indicates a neutral stance for investors. It suggests that while the stock may not offer significant upside potential in the near term, it is not expected to underperform drastically either. This rating is based on a comprehensive evaluation of four key parameters: Quality, Valuation, Financial Trend, and Technicals. Each of these factors contributes to the overall assessment of the stock’s investment appeal.
Quality Assessment
As of 03 August 2026, Themis Medicare Ltd holds an average quality grade. This reflects a mixed operational and financial profile. The company’s ability to service its debt remains a concern, with a notably high Debt to EBITDA ratio of 100.09 times, signalling significant leverage and potential liquidity risks. Additionally, the company’s operating profit has declined sharply over the past five years, with an annualised contraction rate of -175.34%. Such a steep decline in operating profit points to challenges in sustaining long-term growth and operational efficiency.
Valuation Considerations
The valuation grade for Themis Medicare Ltd is classified as risky. The stock is trading at valuations that are elevated compared to its historical averages, which may not be justified given the company’s current earnings profile. Despite a modest positive return of 1.90% over the past year, the company’s profits have fallen by -93.3% during the same period, indicating a disconnect between market pricing and underlying financial performance. Investors should be cautious as the stock’s valuation does not currently reflect a margin of safety.
Financial Trend and Recent Performance
Financially, the company shows some positive signs. The financial grade is positive, supported by recent quarterly results. In the quarter ending March 2026, Themis Medicare Ltd reported a Profit Before Tax (PBT) excluding other income of ₹5.39 crores, which represents a growth of 187.5% compared to the previous four-quarter average. Similarly, the Profit After Tax (PAT) for the quarter stood at ₹8.89 crores, marking an impressive 314.7% increase over the same period. These figures suggest a potential turnaround in profitability in the short term.
However, the company continues to report negative operating profits, with an EBIT of ₹-9.94 crores, underscoring ongoing operational challenges. Furthermore, a significant portion of promoter shares—43.39%—are pledged, which has increased by 40.96% over the last quarter. This elevated pledge level can exert downward pressure on the stock price, especially in volatile or declining markets, adding an element of risk for shareholders.
Technical Outlook
From a technical perspective, the stock is mildly bullish. As of 03 August 2026, Themis Medicare Ltd’s stock price has shown mixed short-term performance: a 1-day gain of 1.76%, a 1-week decline of 0.93%, and a 1-month drop of 9.62%. Over longer periods, the stock has rebounded with a 3-month gain of 9.44% and a 6-month surge of 31.12%. Year-to-date, the stock has appreciated by 6.36%. These movements suggest some investor confidence returning, although volatility remains a factor to consider.
Implications for Investors
The 'Hold' rating reflects a balanced view of Themis Medicare Ltd’s prospects. Investors should recognise that while recent quarterly improvements hint at a possible recovery, the company’s high leverage, risky valuation, and operational losses temper enthusiasm. The stock may be suitable for investors with a moderate risk appetite who are willing to monitor developments closely but are not seeking aggressive growth at this stage.
Summary of Key Metrics as of 03 August 2026
- Mojo Score: 53.0 (Hold Grade)
- Debt to EBITDA Ratio: 100.09 times (high leverage)
- Operating Profit Growth (5 years): -175.34% annualised
- Quarterly PBT (Mar 2026): ₹5.39 crores, +187.5% vs previous 4Q average
- Quarterly PAT (Mar 2026): ₹8.89 crores, +314.7% vs previous 4Q average
- EBIT: ₹-9.94 crores (negative operating profit)
- Promoter Shares Pledged: 43.39%, increased by 40.96% last quarter
- Stock Returns: 1D +1.76%, 1W -0.93%, 1M -9.62%, 3M +9.44%, 6M +31.12%, YTD +6.36%, 1Y +1.90%
Our current monthly pick, this Mid Cap from Automobile Two & Three Wheelers, survived rigorous evaluation against dozens of contenders. See why experts are backing this one!
- - Rigorous evaluation cleared
- - Expert-backed selection
- - Mid Cap conviction pick
Sector and Market Context
Themis Medicare Ltd operates within the Pharmaceuticals & Biotechnology sector, a space characterised by high research and development costs, regulatory challenges, and competitive pressures. Microcap companies in this sector often face volatility due to their size and financial constraints. The current 'Hold' rating reflects these sector-specific risks alongside company-specific factors.
Conclusion
In conclusion, Themis Medicare Ltd’s 'Hold' rating by MarketsMOJO as of 30 June 2026, supported by a Mojo Score of 53, signals a cautious approach for investors. The company’s recent quarterly earnings growth offers some optimism, but significant debt levels, negative operating profits, and risky valuation metrics warrant prudence. Investors should weigh these factors carefully and consider their own risk tolerance before making investment decisions.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
